Table II.
Prognostic analysis of PLCB genes for recurrence-free survival.
| Variable | Patients (n=212) | No. of events | MST (months) | HR (95% CI) | Crude P-value | HR (95% CI) | Adjusted P-valuea |
| PLCB1 | |||||||
| Low expression | 106 | 46 | NA | Ref. | Ref. | ||
| High expression | 106 | 70 | 26.9 | 1.914 (1.318–2.781) | 0.001 | 1.861 (1.273–2.271) | 0.001 |
| PLCB2 | |||||||
| Low expression | 106 | 59 | 36.0 | Ref. | Ref. | ||
| High expression | 106 | 57 | 51.1 | 0.863 (0.599–1.243) | 0.429 | 0.956 (0.654–1.398) | 0.817 |
| PLCB3 | |||||||
| Low expression | 106 | 52 | 54.8 | Ref. | Ref. | ||
| High expression | 106 | 64 | 29.9 | 1.466 (1.015–2.118) | 0.042 | 1.244 (0.853–1.814) | 0.257 |
| PLCB4 | |||||||
| Low expression | 106 | 59 | 46.3 | Ref. | Ref. | ||
| High expression | 106 | 57 | 43.2 | 1.015 (0.705–1.461) | 0.936 | 0.962 (0.664–1.395) | 0.840 |
a
P-values were adjusted for gender, cirrhosis and Barcelona Clinic Liver Cancer stage. Ref., reference value (1); MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; PLCB, phospholipase B. Bold indicates significant P-values.